These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Antiemetics for cancer chemotherapy-induced nausea and vomiting. A review of agents in development. Rizk AN; Hesketh PJ Drugs R D; 1999 Oct; 2(4):229-35. PubMed ID: 10659396 [TBL] [Abstract][Full Text] [Related]
5. Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting. Hesketh PJ Support Care Cancer; 2001 Jul; 9(5):350-4. PubMed ID: 11497388 [TBL] [Abstract][Full Text] [Related]
6. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients? de Wit R; Aapro M; Blower PR Cancer Chemother Pharmacol; 2005 Sep; 56(3):231-8. PubMed ID: 15838653 [TBL] [Abstract][Full Text] [Related]
7. Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban). Morrow GR; Hickok JT; Rosenthal SN Cancer; 1995 Aug; 76(3):343-57. PubMed ID: 8625113 [TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-induced emesis in elderly cancer patients: the role of 5-HT3-receptor antagonists in the first 24 hours. Aapro M; Johnson J Gerontology; 2005; 51(5):287-96. PubMed ID: 16110229 [TBL] [Abstract][Full Text] [Related]
9. Current issues in the management of nausea and vomiting. Gralla RJ Ann Oncol; 1993; 4 Suppl 3():3-7. PubMed ID: 8363996 [TBL] [Abstract][Full Text] [Related]
10. [Prophylaxis of chemotherapy-induced vomiting and nausea]. Tóth J; Szántó J Magy Onkol; 2008 Dec; 52(4):391-4. PubMed ID: 19068468 [TBL] [Abstract][Full Text] [Related]
11. New treatment options for chemotherapy-induced nausea and vomiting. Hesketh PJ Support Care Cancer; 2004 Aug; 12(8):550-4. PubMed ID: 15232725 [TBL] [Abstract][Full Text] [Related]
12. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy. Cunningham RS Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379 [TBL] [Abstract][Full Text] [Related]
13. Reducing chemotherapy-induced nausea and vomiting. Current perspectives and future possibilities. Del Favero A; Roila F; Tonato M Drug Saf; 1993 Dec; 9(6):410-28. PubMed ID: 7510495 [TBL] [Abstract][Full Text] [Related]
14. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting. Herrstedt J Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151 [TBL] [Abstract][Full Text] [Related]
15. Antiemetic strategies for high-dose chemoradiotherapy-induced nausea and vomiting. Spitzer TR; Grunberg SM; Dicato MA Support Care Cancer; 1998 May; 6(3):233-6. PubMed ID: 9629875 [TBL] [Abstract][Full Text] [Related]
16. Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood. Phillips RS; Gopaul S; Gibson F; Houghton E; Craig JV; Light K; Pizer B Cochrane Database Syst Rev; 2010 Sep; (9):CD007786. PubMed ID: 20824866 [TBL] [Abstract][Full Text] [Related]
17. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting. Perez EA Cancer J Sci Am; 1998; 4(2):72-7. PubMed ID: 9532406 [TBL] [Abstract][Full Text] [Related]
18. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Gregory RE; Ettinger DS Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240 [TBL] [Abstract][Full Text] [Related]
19. Optimising antiemetic therapy: what are the problems and how can they be overcome? Aapro M Curr Med Res Opin; 2005 Jun; 21(6):885-97. PubMed ID: 15969889 [TBL] [Abstract][Full Text] [Related]
20. Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy. Ellebaek E; Herrstedt J Curr Opin Support Palliat Care; 2008 Mar; 2(1):28-34. PubMed ID: 18685391 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]